Long-term immune response to Omicron-specific mRNA vaccination in mice, hamsters, and nonhuman primates.

ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron and its subvariants (such as BQ.1, XBB and the latest variants, including XBB.1.16, EG.5, and BA.2.86), as the dominant variants, currently account for almost all new infections in the world due to their high transmissibility and immune escape ability. Omicron-specific mRNA vaccines showed great potential to protect against Omicron infections. However, whether the vaccine could provide long-term protection is unknown. Toward this goal, we evaluated the immunogenicity of a preclinical Omicron (BA.1)-specific mRNA vaccine (S_Omicron-6P) in different animal models. S_Omicron-6P induced the highest levels of antibody titers at 1-2 weeks in different animals after the second dose. Even 9 months after the im

SUBMITTER: Wu Y 

PROVIDER: S-EPMC10724501 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature